Faron update on pipeline progress ahead of R&D Day
Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron provides update on pipeline progress ahead of R&D DayCompany announcement, 16 June 2020 at 9.00 AM (EET) Inside information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today provides an update on the progress of its two clinical stage programmes, Clevegen and Traumakine, ahead of the Company’s virtual R&D Day. Clevegen Clevegen is Faron’s wholly-owned novel precision cancer immunotherapy, targeting Clever-1 positive tumour